Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ADX10059: Additional Phase IIa data

A French Phase IIa trial in 24 patients with GERD that showed 250 mg oral ADX10059 reduced the number of symptomatic episodes vs.

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE